Exosome therapy is a still-experimental cell therapy approach aimed at treating specific diseases using secretions from cells. It’s novel since most attention on cell therapies has been given to using the actual cells themselves. In addition, this approach is a newer idea than using cells as the drug to treat diseases. Interestingly, the term “cell […]
Fact-checking exosome therapy: costs, risks, & lack of data Read More »
As I’ve mentioned recently, it’s my busy time for medical school teaching and not long ago we did a GI lab that included one of my favorite structures in the course: taste buds. Taste buds The medical students seem fascinated with taste buds too. I can tell as their professor when something is particularly interesting
Weekly reads: taste buds, organoids, good news on CRISPR safety Read More »
Stem cell biologist Jacob Hanna has a new startup called Renewal Bio. Its goal is to harvest cells or tissues from human embryo or fetus models for clinical use. I believe that their commercial ambitions have so far outstripped careful thought and discussion in the broader community of researchers. There are major risks here for
‘We don’t want to freak people out’: about that Jacob Hanna human embryo model startup Read More »
I’ve tried to find some time to do some stem cell and other regenerative medicine reading too, but it’s been a busy week of teaching for me as a professor in our new academic year for the UC Davis School of Medicine. I help to teach the Histology part of the first-year curriculum. It’s an
Regenerative medicine reads: retraction, FDA warning, CAR-T, ARM CEO Read More »
Histone proteins such as histone H3 are often popping up in science writing and news sometimes includes specific modified forms of H3 including one that we scientists call H3K27me3. What is in this article What is H3K27me3? | The histone code | H3K27ac and H3K27me3 function | H3K27 and human disease | References The goal of today’s post
Histone code series: H3K27me3 & H3K27ac functions & roles in diseases like DIPG Read More »
I have a soft spot for fibroblasts, perhaps because one of the first immortalized cell lines I ever grew was NIH3T3. These are mouse fibroblasts that have been immortalized. They are very useful for a variety of experiments. I used them to study an oncogene called E2A-PBX1. Experience with fibroblasts including 3T3s I was amazed
Weekly reads: fibroblasts, gene-editing, Mitalipov, personhood, embryos Read More »
Organoids including brain organoids are an exciting, relatively new area of research. This technology is having a powerful impact on biomedical science, which is the focus of today’s post. What’s in this post Definition of organoids | Brain organoids | Challenges for mini-brains | Cutting edge cerebral organoids | References Definition of organoids and brain organoids
How brain organoids are transforming research Read More »
The recent news of Vertex Pharma buying small stem cell biotech ViaCyte and Doug Melton moving to Vertex brought to mind an old stem cell biotech called Advanced Cell Technology (ACT) and its leader, stem cell biologist Dr. Robert Lanza. Years ago, big pharma firm Astellas bought ACT and Lanza moved to be a leader of regenerative
In big shift Dr. Robert Lanza exits Astellas Read More »
The last six months I’ve been spending even more time than usual writing NIH grants (and a few others). The last two weeks have been especially busy on this front as I am getting an R01 renewal out the door. My paper reading lately has been mostly related to the grant writing I’m doing. Still,
Weekly reads: NIH grants, side effect of darker hair, FDA warning, CRISPR Read More »
It’s been mostly a downbeat week on the stem cell news front including a deep revisit by Reuters to the Piero Anversa case that has new revelations. It’s ugly stuff involving other folks too. We’ll start on the iPS cell front, where a trial participant had a teratoma. I’ve had a long-standing interest in the